Loading...
01/10 16:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
Cash, cash equivalents, and short-term investments $20.6 million as of June 30, 2025, compared to $44.9 million as of December 31, 2024. The decrease is attributed to operational expenses.
Cash used in operations $6.4 million for Q2 2025 compared to $13.3 million for Q2 2024, a decrease due to reduced study costs and operational efficiencies.
Research and development expense $2.8 million for Q2 2025 compared to $10.7 million for Q2 2024, a decrease of $7.9 million primarily due to the wind-down of clinical trials for REL-1017, partially offset by increased costs for NDV-01 and sepranolone activities.
General and administrative expense $7.4 million for Q2 2025 compared to $8.1 million for Q2 2024, a decrease of approximately $696,000 due to lower stock-based compensation expense, partially offset by increased employee and consulting service costs.
Net loss $9.9 million for Q2 2025 compared to $17.8 million for Q2 2024, a reduction driven by lower R&D and operational expenses.
NDV-01 for non-muscle invasive bladder cancer (NMIBC): Demonstrated 91% high-grade disease-free status at any time point in Phase II study. Sustained release formulation of gemcitabine and docetaxel designed to improve bladder exposure, minimize toxicity, and simplify administration. Phase III study planned for 2026.
Sepranolone for compulsivity disorders: Targeting Prader-Willi syndrome (PWS) as first indication. Phase II data in Tourette's syndrome showed proof of concept and good tolerability. Phase II study for PWS planned for 2026.
Bladder cancer market: 85,000 new cases annually in the U.S., with 50% being high-grade disease. NDV-01 aims to address this significant and underserved market.
Compulsivity disorders market: PWS affects 350,000 people globally, including 20,000 in the U.S. Sepranolone aims to address this unmet need.
Financial position: $20.6 million cash balance as of June 30, 2025. Reduced cash usage in operations compared to 2024.
Team expansion: Added two experts in bladder cancer and urologic oncology: Dr. Raj Pruthi as Chief Medical Officer and Dr. Yair Lotan as Chair of Clinical Advisory Board.
Pipeline focus: Prioritizing NDV-01 and sepranolone development. Preparing for Phase III and Phase II studies in 2026.
Regulatory and manufacturing preparation: Plans to interact with FDA and scale up production for clinical batches of NDV-01 and sepranolone.
Cash Burn Rate: The company reported a significant decrease in cash reserves, from $44.9 million at the end of 2024 to $20.6 million as of June 30, 2025. This indicates a high cash burn rate, which could pose a risk to the company's ability to sustain operations and fund its clinical programs without additional financing.
Regulatory and Clinical Development Risks: The company plans to initiate Phase III trials for NDV-01 and Phase II trials for sepranolone in 2026. These trials are subject to regulatory approvals and successful completion of preparatory activities, including FDA interactions and manufacturing scale-up. Any delays or failures in these areas could adversely impact timelines and financials.
Supply Chain and Manufacturing Risks: The company needs to transfer production to a contract manufacturer and complete scale-up for clinical batches of NDV-01 and sepranolone. Any disruptions or delays in the supply chain or manufacturing process could hinder the progress of clinical trials.
Financial Sustainability: The company reported a net loss of $9.9 million for Q2 2025 and a decrease in R&D expenses due to the wind-down of previous trials. However, the ramp-up of new programs will likely increase costs, potentially straining financial resources given the current cash position.
Market and Competitive Risks: NDV-01 and sepranolone target competitive and underserved markets. While the products show promise, they face competition from existing therapies and other companies developing similar treatments. Market acceptance and differentiation will be critical for success.
NDV-01 Phase III Study: Relmada plans to initiate a Phase III study for NDV-01 in the first half of 2026. Preparations include interactions with the FDA on trial design and transferring production to a contract manufacturer for clinical batch production.
Sepranolone Proof-of-Concept Study: A proof-of-concept study for sepranolone in Prader-Willi syndrome is planned for the first half of 2026. Preparations include FDA interactions on trial design and setting up a product supply chain with contract manufacturers.
Financial Guidance: Relmada is prioritizing the advancement of NDV-01 and expects to align its cash requirements and runway with its clinical and regulatory strategy. The company had $20.6 million in cash as of June 30, 2025.
The selected topic was not discussed during the call.
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
The earnings call reveals several concerns: an EPS miss, increased cash burn, and reduced cash reserves, suggesting financial instability. Regulatory and competitive risks further exacerbate uncertainties. Despite some optimism in product development, unclear management responses in the Q&A and the lack of guidance add to the negative sentiment. The net loss improvement is overshadowed by operational challenges and financial concerns, leading to a predicted stock movement of -2% to -8%.
The earnings call reveals financial challenges, including a shrinking cash balance and increased cash used in operations, raising liquidity concerns. Despite some positive indicators like reduced net loss and promising initial data for NDV-01, the lack of clear guidance and potential regulatory and operational risks overshadow the positives. The management's vague responses in the Q&A add to the uncertainty. Given these factors, a negative sentiment is warranted, suggesting a potential stock price decline of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
